ASH Impact Series: Wendy Stock, MD - How I Treat ALL in First Complete Remission

2/2/2017

Description

Wendy Stock, MD, discusses the current tools to measure minimal residual disease in acute lymphoblastic leukemia (ALL), how minimal residual disease impacts treatment decisions for ALL, and more. Dr. Stock presented on the topic at the 2016 ASH Meeting on Hematologic Malignancies in a session titled "How I Treat ALL in First Complete Remission: Role of MRD and Molecular Genetics in Treatment Decisions."

Speakers

  • Wendy Stock, MD

back to top